[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody for angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 64, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 58, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bing  Gong Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cynthia A. Sirard M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arjun  Prasad M.B.A., M.P.H.", "title": "Chief Commercial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.39, "open": 6.31, "dayLow": 6.15, "dayHigh": 6.4304, "regularMarketPreviousClose": 6.39, "regularMarketOpen": 6.31, "regularMarketDayLow": 6.15, "regularMarketDayHigh": 6.4304, "payoutRatio": 0.0, "beta": 1.271, "forwardPE": -15.220287, "volume": 1348919, "regularMarketVolume": 1348919, "averageVolume": 2161630, "averageVolume10days": 2002770, "averageDailyVolume10Day": 2002770, "bid": 6.12, "ask": 6.24, "bidSize": 15, "askSize": 15, "marketCap": 1097409152, "fiftyTwoWeekLow": 1.33, "fiftyTwoWeekHigh": 6.88, "allTimeHigh": 11.0, "allTimeLow": 0.765, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 5.67, "twoHundredDayAverage": 3.8441, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 887381184, "profitMargins": 0.0, "floatShares": 107592343, "sharesOutstanding": 177862102, "sharesShort": 21933707, "sharesShortPriorMonth": 21587650, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.1233, "heldPercentInsiders": 0.11281, "heldPercentInstitutions": 0.88179, "shortRatio": 8.65, "shortPercentOfFloat": 0.19489999, "impliedSharesOutstanding": 177862102, "bookValue": 1.18, "priceToBook": 5.2288136, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -65806000, "trailingEps": -0.45, "forwardEps": -0.40538, "enterpriseToEbitda": -12.494, "52WeekChange": 0.98107255, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 6.17, "targetHighPrice": 30.0, "targetLowPrice": 8.0, "targetMeanPrice": 13.57143, "targetMedianPrice": 12.0, "recommendationMean": 1.1875, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 219895008, "totalCashPerShare": 1.236, "ebitda": -71024000, "totalDebt": 9867000, "quickRatio": 17.716, "currentRatio": 17.815, "totalRevenue": 0, "debtToEquity": 4.707, "revenuePerShare": 0.0, "returnOnAssets": -0.23469, "returnOnEquity": -0.37818, "grossProfits": 0, "freeCashflow": -22006376, "operatingCashflow": -45051000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "marketState": "CLOSED", "postMarketChangePercent": 0.0, "postMarketPrice": 6.17, "postMarketChange": 0.0, "regularMarketChange": -0.22, "regularMarketDayRange": "6.15 - 6.4304", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2161630, "fiftyTwoWeekLowChange": 4.84, "fiftyTwoWeekLowChangePercent": 3.6390977, "fiftyTwoWeekRange": "1.33 - 6.88", "fiftyTwoWeekHighChange": -0.71000004, "fiftyTwoWeekHighChangePercent": -0.10319768, "fiftyTwoWeekChangePercent": 98.107254, "corporateActions": [], "postMarketTime": 1771634808, "regularMarketTime": 1771621203, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.44288, "regularMarketPrice": 6.17, "earningsTimestampStart": 1772112600, "earningsTimestampEnd": 1772112600, "earningsCallTimestampStart": 1754913600, "earningsCallTimestampEnd": 1754913600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.45, "epsForward": -0.40538, "epsCurrentYear": -0.41615, "priceEpsCurrentYear": -14.826385, "fiftyDayAverageChange": 0.5, "fiftyDayAverageChangePercent": 0.08818342, "twoHundredDayAverageChange": 2.3259, "twoHundredDayAverageChangePercent": 0.6050571, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]